Novartis in Advanced Talks to Buy Cytokinetics

Swiss drugmaker Novartis (NOVN.S) is in the lead to acquire Cytokinetics (CYTK.O) for a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday. Novartis is poised to prevail in the auction for Cytokinetics, ahead of other bidders that include AstraZeneca (AZN.L) and Johnson & Johnson (JNJ.N), according to the source.

Read the full article: Novartis in Advanced Talks to Buy Cytokinetics //

Source: https://www.reuters.com/markets/deals/novartis-advanced-talks-buy-cytokinetics-wsj-2024-01-08

Leave a Comment

Your email address will not be published.

Scroll to Top